Donepezil use in Alzheimer disease

Annals of Pharmacotherapy

Volumn 32, Issue 1, 1998, Pages 70-77

  Barner, Erica L ^a   Gray, Shelly L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer disease; Donepezil

Indexed keywords

CYTOCHROME; DONEPEZIL; FUROSEMIDE; TACRINE; WARFARIN;

ADULT; AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; COGNITION; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG ELIMINATION; DRUG SAFETY; ENZYME ANALYSIS; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INSOMNIA; LIVER FUNCTION TEST; MALE; MUSCLE CRAMP; NAUSEA; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0031910978     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17150     Document Type: Review

References (25)

1. Peskind ER. Neurobiology of Alzheimer's disease. J Clin Psychiatry 1996;57(suppl 14):5-8.
2. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cholinergic innervation. Science 1983;219:1184-90.
3. Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease: mechanisms of actions and prospects for cognitive enhancing medications. Med Clin North Am 1994;78:911-34.
4. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994;28:744-51.
5. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-((5,6-dimethoxy-1-oxoindan-2-yl)methyl)piperidine hydrochloride and related compounds. J Med Chem 1995;38:4821-9.
6. Rogers SL, Friedhoff LT, Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
7. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease (letter). Lancet 1976;2:1403.
8. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Tox 1993; 31:223-9.
9. Package insert. Aricept (donepezil hydrochloride). Teaneck, NJ: Eisai Inc., November 1996.
10. Ohnishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, Yamazaki K, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly patients. J Clin Pharmacol 1993;33:1086-91.
11. Cognex expanded access proposed by FDA as part of "program of further study": Warner-Lambert will support NDA studies with other data by April 1. F-D-C Rep 1991;March 25:4-9.
12. Talwalker S, Overall JE, Srirama MK, Gracon SI. Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's disease assessment scale. J Geriatr Psychiatry Neurol 1996;9:39-46.
13. Stem RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-6.
14. Kramer-Ginsberg E, Mohs RC, Aryan M, Lobel D, Silverman J, Davidson M, et al. Clinical predictors of course for Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988; 24:458-62.
15. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
16. Rogers SL, Doody R, Mohs R, Friedhoff LT. E2020 produces both clinical global and cognitive test improvements in patients with mild to moderately severe Alzheimer's disease: result of a 30-week Phase III trial (abstract). Neurology 1996;46(suppl):A217.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-44.
18. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Eur Neuropsychopharmacol 1995;5:386 (P-8-21).
19. 1997 Drug topics red book. Montvale, NJ: Medical Economics, 1997.
20. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:3523-9.
21. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-77.
22. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
23. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
24. Package insert. Cognex (tacrine). Morris Plains, NJ (in press).
25. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154(suppl 5):1-39.